Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma

• Status: Completed
• Trial end date: 2013-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients will receive Bortezomib, Dexamethasone, and Doxorubicin in 21 day cycles a total of 4 to 8 times (based on response to the treatment). Patients will also receive acetyl-L-carnitine (ALCAR) daily.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison
• Collaborator: Millennium Pharmaceuticals, Inc.
• Treatments: Acetylcarnitine; BB 1101; Bortezomib; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Doxorubicin; Liposomal doxorubicin

Criteria

Inclusion Criteria:

• Patients with previously treated multiple myeloma with measurable serum or urine monoclonal protein.

Exclusion Criteria:

• Patients with previous doxorubicin treatment totaling 220 mg/m2 or more

• LVEF less than 45%

• Patients with >grade II sensory neuropathy at baseline as assessed by the PI will be excluded

• No history of seizures as ALCAR may lower the seizure threshold

• Known HIV infection

• Current pregnancy.